EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antibody-Dependent Enhancement Activity of a Plant-Made Vaccine against West Nile Virus

Haiyan Sun, Dhiraj Acharya, Amber M Paul, Huafang Lai, Junyun He, Fengwei Bai, Qiang Chen iD

Vaccines · 17.01.2023 · 11 (2) · 197

DOI: 10.3390/vaccines11020197 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 17.01.2023. Verfasst von Haiyan Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Biodesign Institute and School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

West Nile virus (WNV) causes annual outbreaks globally and is the leading cause of mosquito-borne disease in Unite States. In the absence of licensed therapeutics, there is an urgent need to develop effective and safe human vaccines against WNV. One of the major safety concerns for WNV vaccine development is the risk of increasing infection by related flaviviruses in vaccinated subjects via antibody-dependent enhancement of infection (ADE). Herein, we report the development of a plant-based vaccine candidate that provides protective immunity against a lethal WNV challenge mice, while minimizes the risk of ADE for infection by Zika (ZIKV) and dengue (DENV) virus. Specifically, a plant-produced virus-like particle (VLP) that displays the WNV Envelope protein domain III (wDIII) elicited both high neutralizing antibody titers and antigen-specific cellular immune responses in mice. Passive transfer of serum from VLP-vaccinated mice protected recipient mice from a lethal challenge of WNV infection. Notably, VLP-induced antibodies did not enhance the infection of Fc gamma receptor-expressing K562 cells by ZIKV or DENV through ADE. Thus, a plant-made wDIII-displaying VLP presents a promising WNV vaccine candidate that induces protective immunity and minimizes the concern of inducing ADE-prone antibodies to predispose vaccinees to severe infection by DENV or ZIKV.

Schlagwörter

Stichwörter der Autor:innen

West Nile virus (WNV)Zika virus (ZIKV)antibody-dependent enhancement (ADE)dengue virus (DENV)domain III (DIII)plant-produced vaccinevaccinevirus-like particle (VLP)

Autor:innen und Institutionen

  • The Biodesign Institute and School of Life Sciences, Arizona State University, Tempe, AZ 85287, USA.
  • Department of Cell and Molecular Biology, University of Southern Mississippi, Hattiesburg, MS 39406, USA.

ORCID-Profile: Qiang Chen

Förderung

  • NIGMS NIH HHS
  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Sun, H., Acharya, D., Paul, A. M., Lai, H., He, J., Bai, F., & Chen, Q. (2023). Antibody-Dependent Enhancement Activity of a Plant-Made Vaccine against West Nile Virus. Vaccines, 11(2), 197. https://doi.org/10.3390/vaccines11020197

Vancouver

Sun H, Acharya D, Paul AM, Lai H, He J, Bai F, et al. Antibody-Dependent Enhancement Activity of a Plant-Made Vaccine against West Nile Virus. Vaccines. 2023;11(2):197. doi:10.3390/vaccines11020197

BibTeX
@article{Sun2023,
  author = {Sun, Haiyan and Acharya, Dhiraj and Paul, Amber M and Lai, Huafang and He, Junyun and Bai, Fengwei and Chen, Qiang},
  title = {Antibody-Dependent Enhancement Activity of a Plant-Made Vaccine against West Nile Virus},
  journal = {Vaccines},
  year = {2023},
  volume = {11},
  number = {2},
  pages = {197},
  doi = {10.3390/vaccines11020197}
}
Kostenlos starten →